|
Elan Corporation PLC - Company Profile Snapshot
| Company Profile: |
Elan Corporation PLC |
| Ticker: |
DRX |
| Exchanges: |
NYSE LON DUB |
| 2008 Sales: |
518,400,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Diversified Drugs, Cosmetics, & Health Care |
| Country: |
IRELAND |
| Employees: |
1687 |
Business Description
Elan Corporation PLC. The Group's principal activity is discovering, developing, manufacturing and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. The Group's operations are carried out through two divisions. Elan Drug Technologies focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Biopharmaceuticals relates to the research, development and commercial activities in the areas of autoimmune diseases, neurodegenerative diseases and specialty business. The Group's product brands are Azactam, Maxipime, MXDAS, NanoCrystal, Naprelan, Prialt, SODAS, Tysabri and Verelan.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
